search
Back to results

Effect of Transcutaneous Electrical Nerve Stimulation in Peripheral Artery Disease TENS-PAD Study / TENS-AOMI (TENS-PAD)

Primary Purpose

Peripheral Artery Disease

Status
Terminated
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Transcutaneous electrical nerve stimulation (TENS)
SHAM Transcutaneous electrical nerve stimulation (TENS)
Sponsored by
University Hospital, Toulouse
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Peripheral Artery Disease focused on measuring peripheral artery disease, transcutaneous electrical nerve stimulation, walking ability, endothelial function

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Unilateral Leriche stage II PAD, admitted to cardiovascular Rehabilitation Unit
  • Men or women
  • Able to take part in an out-patient rehabilitation programme
  • Clinically stable
  • Sedentary
  • Provided informed consent to participate in the study

Exclusion Criteria:

  • Ward of court
  • Walking disorders related to orthopaedic or neuromuscular disease
  • Participation in a structured physical reconditioning programme in the month before the study
  • Renal insufficiency requiring dialysis
  • Known and documented myopathy
  • Progressive cancer
  • Associated progressive disease causing a deterioration in general health
  • Participation in another research protocol
  • Skin disorder making it impossible to use TENS
  • Absolute contra-indication to physical activity
  • Presence of pacemaker / defibrillator
  • Pregnant women in the 1st trimester / 12 weeks

Sites / Locations

  • University Hospital of Dijon
  • University Hospital of Nîmes
  • Clinique de Saint-Orens
  • Toulouse University Hospital (CHU de Toulouse)

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

1 - TENS group

2 - SHAM group

Arm Description

The treatment will consist of Transcutaneous electrical nerve stimulation (TENS): stimulation of the leg (frequency of 10 Hz, Biphasic, with a pulse width of 200 µs, maximal intensity below motor threshold), 45 minutes per day, in the morning before the exercise rehabilitation programme, for 3 weeks, 5 days per week.

SHAM Transcutaneous electrical nerve stimulation (TENS) : the stimulation placebo will be delivered according to the same modalities as for the TENS group but with a voltage level that vanishes automatically after 10 seconds of stimulation.

Outcomes

Primary Outcome Measures

walking distance without pain (in meters)
the evolution of the claudication distance between the start and the end of the study (1 session of TENS each day , 15 days in total) in the two intervention group (TENS vs SHAM). Measure of change between inclusion and end of study.

Secondary Outcome Measures

maximal oxygen consumption (VO2peak in ml.min)
maximal oxygen consumption (VO2peak in ml.min) Measure of change between inclusion and end of study.

Full Information

First Posted
January 8, 2016
Last Updated
January 20, 2022
Sponsor
University Hospital, Toulouse
Collaborators
Ministry of Health, France
search

1. Study Identification

Unique Protocol Identification Number
NCT02678403
Brief Title
Effect of Transcutaneous Electrical Nerve Stimulation in Peripheral Artery Disease TENS-PAD Study / TENS-AOMI
Acronym
TENS-PAD
Official Title
Efficacy of Transcutaneous Electrical Nerve Stimulation in the Improvement of Walking Distance in Patients With Peripheral Artery Disease With Intermittent Claudication
Study Type
Interventional

2. Study Status

Record Verification Date
January 2022
Overall Recruitment Status
Terminated
Why Stopped
principal investigator left Toulouse hospital
Study Start Date
August 16, 2018 (Actual)
Primary Completion Date
September 16, 2019 (Actual)
Study Completion Date
September 16, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Toulouse
Collaborators
Ministry of Health, France

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Purpose: The investigators team recently carried out a proof of concept study testing the efficacy of one single 45-minute session of 10 Hz TENS prior to walking, versus placebo. In this randomized study, the investigators found that TENS significantly delayed pain onset and increased the pain-free walking distance in patients with class II PAD. From these encouraging results, the investigators now seek to assess the efficacy of an intervention that includes the daily use of TENS for 3 weeks (5 days a week) on walking distance in PAD (Leriche-Fontaine stage II). Methods/Design: prospective multicentre study / randomized controlled trial / double blinding.
Detailed Description
Interventions (2 groups): Experimental group (TENS group): the treatment will consist of stimulation of the leg (frequency of 10 Hz, Biphasic, with a pulse width of 200 µs, maximal intensity below motor threshold), 45 minutes per day, in the morning before the exercise rehabilitation programme, for 3 weeks, 5 days per week. Control group (group SHAM): the stimulation placebo will be delivered according to the same modalities as for the TENS group but with a voltage level that vanishes automatically after 10 seconds of stimulation. 15 days of interventions (TENS or SHAM) between J0 and J23, End of study for patient at J24-J25, two days for the last analyses who are the same of inclusion's visit J0. Primary outcome: walking distance (metres) measured on a treadmill with a standardized protocol. Secondary outcomes: transcutaneous oxygen pressure (TcPO2) measured during a Strandness exercise test, peak oxygen uptake (VO2 peak) (ml.min.kg-1), endothelial function (EndoPAT®), ankle-brachial pressure index, body mass index, lipid profile (LDL-C, HDL-C, Triglycerides), fasting glycaemia, HbA1c, WELCH questionnaire.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Artery Disease
Keywords
peripheral artery disease, transcutaneous electrical nerve stimulation, walking ability, endothelial function

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
8 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1 - TENS group
Arm Type
Experimental
Arm Description
The treatment will consist of Transcutaneous electrical nerve stimulation (TENS): stimulation of the leg (frequency of 10 Hz, Biphasic, with a pulse width of 200 µs, maximal intensity below motor threshold), 45 minutes per day, in the morning before the exercise rehabilitation programme, for 3 weeks, 5 days per week.
Arm Title
2 - SHAM group
Arm Type
Sham Comparator
Arm Description
SHAM Transcutaneous electrical nerve stimulation (TENS) : the stimulation placebo will be delivered according to the same modalities as for the TENS group but with a voltage level that vanishes automatically after 10 seconds of stimulation.
Intervention Type
Device
Intervention Name(s)
Transcutaneous electrical nerve stimulation (TENS)
Intervention Description
Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
Intervention Type
Device
Intervention Name(s)
SHAM Transcutaneous electrical nerve stimulation (TENS)
Intervention Description
Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
Primary Outcome Measure Information:
Title
walking distance without pain (in meters)
Description
the evolution of the claudication distance between the start and the end of the study (1 session of TENS each day , 15 days in total) in the two intervention group (TENS vs SHAM). Measure of change between inclusion and end of study.
Time Frame
Change between J0 and J25 (15 days)
Secondary Outcome Measure Information:
Title
maximal oxygen consumption (VO2peak in ml.min)
Description
maximal oxygen consumption (VO2peak in ml.min) Measure of change between inclusion and end of study.
Time Frame
Change between J0 and J25 (15 days)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Unilateral Leriche stage II PAD, admitted to cardiovascular Rehabilitation Unit Men or women Able to take part in an out-patient rehabilitation programme Clinically stable Sedentary Provided informed consent to participate in the study Exclusion Criteria: Ward of court Walking disorders related to orthopaedic or neuromuscular disease Participation in a structured physical reconditioning programme in the month before the study Renal insufficiency requiring dialysis Known and documented myopathy Progressive cancer Associated progressive disease causing a deterioration in general health Participation in another research protocol Skin disorder making it impossible to use TENS Absolute contra-indication to physical activity Presence of pacemaker / defibrillator Pregnant women in the 1st trimester / 12 weeks
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marc LABRUNEE, MD
Organizational Affiliation
University Hospital, Toulouse
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital of Dijon
City
Dijon
ZIP/Postal Code
21079
Country
France
Facility Name
University Hospital of Nîmes
City
Nîmes
Country
France
Facility Name
Clinique de Saint-Orens
City
Saint-Orens de Gameville
ZIP/Postal Code
31650
Country
France
Facility Name
Toulouse University Hospital (CHU de Toulouse)
City
Toulouse
ZIP/Postal Code
31059
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
28797281
Citation
Besnier F, Senard JM, Gremeaux V, Riedel M, Garrigues D, Guiraud T, Labrunee M. The efficacy of transcutaneous electrical nerve stimulation on the improvement of walking distance in patients with peripheral arterial disease with intermittent claudication: study protocol for a randomised controlled trial: the TENS-PAD study. Trials. 2017 Aug 10;18(1):373. doi: 10.1186/s13063-017-1997-1.
Results Reference
derived

Learn more about this trial

Effect of Transcutaneous Electrical Nerve Stimulation in Peripheral Artery Disease TENS-PAD Study / TENS-AOMI

We'll reach out to this number within 24 hrs